Navidea Biopharmaceuticals, INC.: directors' dealings · United States · SEC (Form 4)

About Navidea Biopharmaceuticals, INC.

Navidea Biopharmaceuticals, Inc. (ticker: NAVB) is a United States-based biopharmaceutical company focused on precision medicine and immuno-targeted radiopharmaceuticals. The company has been associated with the NYSE American market within the broader U.S. listed healthcare universe, and its operating headquarters are in Dublin, Ohio, United States. From an international equity perspective, Navidea is best understood as a highly specialized microcap biotech rather than a broad commercial pharma platform: its value proposition has historically depended on intellectual property, regulatory approvals, and clinical validation rather than scale manufacturing or diversified product sales. The company was formerly known as Neoprobe Corporation and changed its name in 2012 as part of a strategic shift toward precision diagnostic and therapeutic pharmaceuticals. ([stockanalysis.com](https://stockanalysis.com/quote/otc/NAVBQ/company/?utm_source=openai)) Navidea’s core scientific franchise has centered on the Manocept™ platform, an immuno-targeting backbone designed to identify sites and pathways of disease that are otherwise difficult to detect, particularly through macrophage targeting and CD206-binding biology. The company’s best-known commercial product has been Lymphoseek® (technetium Tc 99m tilmanocept), an FDA-approved radiopharmaceutical used for lymphatic mapping and sentinel lymph node biopsy support in certain cancers, including breast cancer, melanoma, and oral cavity squamous cell carcinoma. A major corporate milestone came in 2017, when Navidea sold the North American rights to Lymphoseek to Cardinal Health, which materially changed the business model by reducing direct commercial revenues and increasing reliance on R&D, partnerships, and the monetization of technology assets. ([navidea.com](https://www.navidea.com/news-media/press-releases/detail/45/fda-approves-navideas-lymphoseek-technetium-tc-99m?utm_source=openai)) Since then, management has positioned the company as a precision immuno-diagnostic and immuno-therapeutic developer with exploratory programs in rheumatoid arthritis, Kaposi’s sarcoma, inflammatory disease, and other macrophage-driven indications. That makes Navidea a niche player in the intersection of nuclear medicine, molecular imaging, and targeted biologic delivery. Its competitive position is therefore scientific rather than commercial: the company is competing for clinical relevance, regulatory progress, and capital access, not for broad market share against large pharma incumbents. For investors, that implies asymmetric upside potential but also substantial execution, financing, and regulatory risk. ([navidea.com](https://www.navidea.com/news-media/press-releases/detail/167/navidea-forms-macrophage-therapeutics-business-unit-to?utm_source=openai)) Geographically, Navidea remains primarily U.S.-anchored, with its business, filings, and investor base centered in the United States, while it has also maintained European legal entities to address post-Brexit operating needs. One of the most important recent developments is that Navidea filed a voluntary Chapter 11, Subchapter V bankruptcy petition on October 1, 2025. For equity holders, this is a critical data point: it signals financial distress, may affect trading liquidity and governance, and raises questions about dilution, restructuring outcomes, and the residual value of NAVB common stock. In short, Navidea is a technology-driven biotech with legitimate scientific assets, but currently one that investors must assess through the lens of restructuring risk as much as through product opportunity. ([navidea.com](https://www.navidea.com/contact?utm_source=openai))